Modified Release Posaconazole in Patients With Cystic Fibrosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03421366|
Recruitment Status : Unknown
Verified December 2017 by Bayside Health.
Recruitment status was: Not yet recruiting
First Posted : February 5, 2018
Last Update Posted : February 5, 2018
|Condition or disease||Intervention/treatment|
|Cystic Fibrosis||Drug: Posaconazole|
Use of antifungals has increased in people with cystic fibrosis. Aspergillus is the dominant fungal pathogen in this patient population and thus far, voriconazole has been used first line. Apart from recurrent and chronic lung infections, people with cystic fibrosis can also have problems with their gastrointestinal tract and absorption, and can develop chronic liver disease. As a consequence, they are at high-risk for not achieving adequate antifungal levels, which may be due to altered oral bioavailability, and they may be more susceptible to hepatic toxicities.
This study will evaluate the use of the newer modified release, once daily formulation of posaconazole in people with cystic fibrosis to identify if there is any difference in the bioavailability of the drug due to the effect of cystic fibrosis on the gastrointestinal tract. This newer formulation of once daily posaconazole is approved by the Therapeutic Goods Administration (TGA) and available on the Pharmaceutical Benefits Scheme (PBS) since March 2015. The newer formulation has the potential to overcome one of the major challenges with antifungals in cystic fibrosis; oral bioavailability. Posaconazole also appears to have reduced hepatotoxicity. This study will focus on the safety and tolerability of the drug, as well as pharmacological and microbiological endpoints.
20 eligible participants will be enrolled and have a
- Pre-treatment sputum will be collected as standard of care.
- Posaconazole serum levels will be taken at days 2, 5 and 7. (Day 5 and 7 as standard of care).
- renal and liver function assessed whilst on treatment as standard of care.
- followed up for 30 days to assess tolerability and monitor for the development of liver toxicity
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Modified Release Posaconazole in Patients With Cystic Fibrosis|
|Estimated Study Start Date :||February 5, 2018|
|Estimated Primary Completion Date :||February 5, 2019|
|Estimated Study Completion Date :||February 5, 2020|
Cystic Fibrosis on Posaconazole
A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
- Serum levels of posaconazole in patients with cystic fibrosis taking the newer modified release once daily oral formulation. [ Time Frame: 7 days ]Posaconazole serum levels at days 2, 5 and 7
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03421366
|Contact: Janine Roney, BHSc RN MPHemail@example.com|
|Contact: Anton Peleg, MBBS FRACP PhDfirstname.lastname@example.org|